About Vicinitas Therapeutics

Vicinitas Therapeutics utilizes its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore levels of degraded proteins linked to cancer and genetic disorders. This technology targets protein instability and haploinsufficiency, providing healthcare professionals with novel therapeutic options.

```xml <problem> Many diseases, including cancers and genetic disorders, are caused by reduced levels of specific proteins within cells. Current therapeutic approaches often fail to address these conditions effectively because they do not directly restore the levels of these degraded proteins. This protein instability and haploinsufficiency limit treatment options for healthcare professionals. </problem> <solution> Vicinitas Therapeutics is developing a new class of medicines using its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform. This technology works by selectively targeting and inhibiting deubiquitinase (DUB) enzymes, which are responsible for removing ubiquitin tags from proteins and marking them for degradation. By inhibiting these DUBs, the DUBTAC platform prevents the degradation of specific target proteins, thereby restoring their levels within the cell. This approach aims to address diseases caused by protein instability and haploinsufficiency, offering a novel therapeutic strategy. </solution> <features> - DUBTAC platform technology for targeted protein stabilization. - Selective targeting of deubiquitinase (DUB) enzymes. - Restoration of protein levels in cells affected by degradation. - Potential application in cancer and genetic disorders. </features> <target_audience> The primary target audience includes healthcare professionals seeking novel therapeutic options for diseases caused by protein instability and haploinsufficiency, as well as patients suffering from these conditions. </target_audience> ```

What does Vicinitas Therapeutics do?

Where is Vicinitas Therapeutics located?

Vicinitas Therapeutics is based in South San Francisco, United States.

How much funding has Vicinitas Therapeutics raised?

Vicinitas Therapeutics has raised 65000000.

Location

South San Francisco, United States

Funding

65000000

Employees

39 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Vicinitas Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

vicinitas.com 2K+

South San Francisco, United States

Funding

Estimated Funding

$50M+

Team (30+)

No team information available.

Company Description

Problem

Many diseases, including cancers and genetic disorders, are caused by reduced levels of specific proteins within cells. Current therapeutic approaches often fail to address these conditions effectively because they do not directly restore the levels of these degraded proteins. This protein instability and haploinsufficiency limit treatment options for healthcare professionals.

Solution

Vicinitas Therapeutics is developing a new class of medicines using its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform. This technology works by selectively targeting and inhibiting deubiquitinase (DUB) enzymes, which are responsible for removing ubiquitin tags from proteins and marking them for degradation. By inhibiting these DUBs, the DUBTAC platform prevents the degradation of specific target proteins, thereby restoring their levels within the cell. This approach aims to address diseases caused by protein instability and haploinsufficiency, offering a novel therapeutic strategy.

Features

DUBTAC platform technology for targeted protein stabilization.

Selective targeting of deubiquitinase (DUB) enzymes.

Restoration of protein levels in cells affected by degradation.

Potential application in cancer and genetic disorders.

Target Audience

The primary target audience includes healthcare professionals seeking novel therapeutic options for diseases caused by protein instability and haploinsufficiency, as well as patients suffering from these conditions.